NCT04521582

Brief Summary

The investigators will evaluate whether a system involving Female Community Health Volunteers (FCHVs) and facility-based community health workers (FB-CHWs) of Health Post (Auxiliary Health Workers, Auxiliary Nurse Midwives and Health Assistant) can contribute to improving hypertension care in rural Nepal. This study will be conducted in Rupa (active group) and Biruwa (comparison group) Rural Municipality of Gandaki province and enroll at least 736 hypertensive adults (322 in Rupa Rural Municipality and 414 in Biruwa Rural Municipality) who are aged 25-70 years, not taking antihypertensive medication, not pregnant and not breastfeeding, free of prior cardiovascular disease, chronic kidney disease, and diabetes. In Rupa Municipality, eligible participants will be able to receive amlodipine, one of the most frequently used antihypertensive medications, from FB-CHWs at Health Posts and five times (including baseline and end of study) of lifestyle counseling by FCHVs, whereas participants in Biruwa Municipality will receive the usual care plus three times (including baseline and end of study) of lifestyle counseling by FCHVs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,428

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2021

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 17, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 20, 2020

Completed
8 months until next milestone

Study Start

First participant enrolled

April 27, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2022

Completed
Last Updated

July 29, 2022

Status Verified

July 1, 2022

Enrollment Period

12 months

First QC Date

August 17, 2020

Last Update Submit

July 27, 2022

Conditions

Keywords

HypertensionCommunity Health WorkerMedicationAmlodipineNepal

Outcome Measures

Primary Outcomes (2)

  • Mean change in systolic blood pressure

    To assess the longitudinal association of the intervention with changes in blood pressure over time, linear mixed effect models with a three-level hierarchical approach will be used.

    One year

  • Mean change in diastolic blood pressure

    To assess the longitudinal association of the intervention with changes in blood pressure over time, linear mixed effect models with a three-level hierarchical approach will be used.

    One year

Secondary Outcomes (1)

  • Percentage of hypertension control (<140/90) among study participants

    One year

Study Arms (2)

Active Group

EXPERIMENTAL

Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within \~1 week and measure blood pressure again. If found high, the participant will be referred to the nearest Health Post. At the Health Posts, if FB-CHWs confirms the diagnosis of hypertension, they will prescribe amlodipine 5 mg/d according to the study protocol and ask the patient to return in \~2 weeks. If blood pressure is controlled (\<140/90 mmHg) after \~2 weeks, FB-CHWs will refill amlodipine 5 mg/d for 3 months. If not, FB-CHWs will increase the dose to 10 mg/d and follow up in \~2 weeks. If still not controlled with amlodipine 10 mg, FB-CHWs will refer the patient to the Regional Hospital in Pokhara. In addition, FCHVs will visit patients' homes 3 times (at 3-, 6-, and 9-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.

Drug: AmlodipineBehavioral: Lifestyle counselling

Comparison Group

ACTIVE COMPARATOR

Participants will be first screened for their blood pressure and asked a few questions to determine eligibility. For eligible participants, FCHV will visit within a week or so and measure the blood pressure again. If found high, the participant will be referred to a healthcare facility ("the usual care") which can diagnose and manage hypertension. In addition, FCHVs will visit patients' homes once (around 3-month), provide lifestyle counseling, and follow up the adherence to hypertension treatment.

Behavioral: Lifestyle counselling

Interventions

The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).

Active Group

Female Community Health Volunteer will provide lifestyle counseling at the participant's home

Active GroupComparison Group

Eligibility Criteria

Age25 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Between 25-70 years old
  • Systolic blood pressure 140-179 mmHg or diastolic blood pressure 90-119 mmHg
  • Do not have a plan to leave the study municipality within a year

You may not qualify if:

  • Use of antihypertensive medication in the last two weeks
  • History of stroke, heart attack, heart failure, or chronic kidney disease
  • History of diabetes meritus
  • Pregnant or any plan to be pregnant in a year
  • Breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Rupa Rural Municipality

Kāski̇̄, Gandaki, 33700, Nepal

Location

Biruwa Rural Municipality

Syāṅjā, Gandaki, 33800, Nepal

Location

MeSH Terms

Conditions

Essential HypertensionHypertension

Interventions

Amlodipine

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

DihydropyridinesPyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Kunihiro Matsushita

    Johns Hopkins Bloomberg School of Public Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 17, 2020

First Posted

August 20, 2020

Study Start

April 27, 2021

Primary Completion

April 20, 2022

Study Completion

July 20, 2022

Last Updated

July 29, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations